Medwell Capital grants stock options

    




 EDMONTON, Jan. 25, 2012 /CNW/ - Medwell Capital Corp. ("Medwell")  announced today that pursuant to its stock option plan the Company has  granted options to directors, officers, employees and consultants  entitling them to purchase up to 3,305,000 common shares at a price of  $0.13 per share on or before January 3, 2021. 

 For further information please visit www.medwellcapital.com. 

 Forward-looking statement 

 Information in this news release that is not current or historical  factual information may constitute forward-looking information within  the meaning of securities laws. Implicit in this information,  particularly in respect of the future outlook of Medwell, and  anticipated events or results, are assumptions based on beliefs of  Medwell's senior management as well as information currently available  to it. While these assumptions were considered reasonable by Medwell at  the time of preparation, they may prove to be incorrect. Readers are  cautioned that actual results are subject to a number of risks and  uncertainties, including the availability of funds and resources to  pursue R&D projects, the successful and timely completion of clinical  studies, the ability of Medwell to take advantage of business  opportunities in the biomedical industry, the granting of necessary  approvals by regulatory authorities as well as general economic, market  and business conditions, and could differ materially from what is  currently expected. 

 Neither the TSX Venture Exchange nor its Regulation Services Provider  (as that term is defined in policies of the TSX Venture Exchange)  accepts responsibility for the adequacy or accuracy of this release. 

Medwell Capital Corp.


CONTACT:  For further information about Medwell please contact:Tony Hesby                      Ross MarshallCora Klein                      Investor RelationsMedwell Capital Corp            416-815-0700 ext. 238780-413-7152                    [e-mail]-mail: [e-mail] 


    

Copyright